Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) - Pipeline Review, H1 2016

  • ID: 3802803
  • Report
  • 40 pages
  • Global Markets Direct
1 of 5
Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) - Pipeline Review, H1 2016

Summary

‘Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) - Pipeline Review, H1 2016’, provides in depth analysis on Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1)
- The report reviews Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
List of Tables

List of Figures

Introduction

Report Coverage

Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) Overview

Therapeutics Development

Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) - Products under Development by Stage of Development

Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) - Products under Development by Therapy Area

Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) - Products under Development by Indication

Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) - Products under Development by Companies

Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) - Companies Involved in Therapeutics Development

AbbVie Inc.

Amgen Inc.

Nemucore Medical Innovations, Inc.

Sanofi

Vertex Pharmaceuticals Incorporated

Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) - Drug Profiles

AMG-900 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

danusertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ilorasertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMI-900 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-156497 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VE-465 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) - Dormant Projects

Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 40List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by AbbVie Inc., H1 2016

Pipeline by Amgen Inc., H1 2016

Pipeline by Nemucore Medical Innovations, Inc., H1 2016

Pipeline by Sanofi, H1 2016

Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Dormant Projects (Contd..2), H1 2016

Dormant Projects (Contd..3), H1 2016

Dormant Projects (Contd..4), H1 2016

Discontinued Products, H1 2016 38List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
According to the author's, recently published report 'Aurora Kinase C - Pipeline Review, H1 2016'; Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.

Furthermore, the author says; Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) Aurora Kinase C is a member of the Aurora subfamily of serine/threonine protein kinases. Aurora Kinase C is a chromosomal passenger protein that forms complexes with Aurora-B and inner centromere proteins and plays an important role in organizing microtubules in relation to centrosome function during mitosis. It is over expressed in several cancer cell lines and involved in oncogenic signal transduction.

The report 'Aurora Kinase C - Pipeline Review, H1 2016' outlays comprehensive information on the Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Aurora Kinase C (Aurora 3 or Serine/Threonine-Protein Kinase 13 or Serine/Threonine-Protein Kinase Aurora-C or EC 2.7.11.1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 3 respectively.
Note: Product cover images may vary from those shown
5 of 5
AbbVie Inc.
Amgen Inc.
Nemucore Medical Innovations, Inc.
Sanofi
Vertex Pharmaceuticals Incorporated
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll